Journal of Taibah University Medical Sciences

From empirical to phenotype-guided pharmacotherapy of chronic orofacial pain: a structured review and quantitative synthesis of epidemiological, pharmacological, psychophysical and dental evidence

Journal of Taibah University Medical Sciences

Date: 12-10-2026

Volume: 21 · Issue: 5 · Pages: 1199–1207

Show more

Structured Review

From empirical to phenotype-guided pharmacotherapy of chronic orofacial pain: a structured review and quantitative synthesis of epidemiological, pharmacological, psychophysical and dental evidence

Show more

Abstract

Background

Chronic orofacial pain (OFP) comprises musculoskeletal, neuropathic and nociplastic disorders, yet first-line drug selection remains largely empirical and is frequently extrapolated from spinal and peripheral neuropathic pain.

Objective

To quantify the evidence underpinning pharmacotherapy of the four principal ICOP-2020 disorders and to appraise psychophysical, neurophysiological and dental markers as candidate predictors of treatment response.

Methods

Structured review of PubMed/MEDLINE and Cochrane sources to October 2026 (meta-analyses, randomised controlled trials [RCTs] and large observational cohorts). Estimates were extracted as reported; where only counts or confidence intervals were available, odds/risk ratios with 95% CI and exact two-sided p values were computed (Fisher’s exact test; Altman–Bland method).

Results

Prevalence spanned three orders of magnitude, from 31.1% for temporomandibular joint disorders to 0.03% for persistent idiopathic facial pain. OFP-specific randomised evidence was small (burning mouth syndrome: 23 RCTs, 1,121 participants), whereas neuropathic-pain recommendations rest on 313 trials (48,789 participants) that excluded idiopathic OFP; first-line numbers needed to treat increased between 2015 and 2025 (tricyclics 3.6→4.6; SNRIs 6.4→7.4). Patients with TMD had lower remote pressure pain thresholds (SMD −1.92; p<0.01), and non-paroxysmal OFP showed enhanced temporal summation (SMD 0.30; p=0.002), whereas impaired conditioned pain modulation (CPM) did not reach significance (p=0.066; I²=98%). Mechanism-stratified studies outside the face showed phenotype-dependent efficacy (CPM–duloxetine r=0.628, p<0.001; oxcarbazepine phenotype interaction p=0.047). Bruxism was associated with TMD (OR 2.25; p<0.001), but self-reported sleep bruxism discriminated cases from controls (OR 6.89; p<0.001) whereas polysomnography did not (OR 0.88; p=0.78).

Conclusions

Current evidence supports, but has not yet tested, phenotype-guided first-line drug selection in chronic OFP. Prospective trials combining standardised psychophysics, trigeminal neurophysiology and instrumentally verified dental factors are required; a testable phenotype-to-drug framework is proposed.

Authors and affiliations

Malika M. Giyazova, PhD 0000-0002-9688-3084
Associate Professor, Department of Dentistry, Asia International University, Bukhara, Uzbekistan
Corresponding author
malikagiyazova85@gmail.com

Siddik Sh. Olimov, DSc, Professor
Head of the Department of Prosthetic Dentistry and Orthodontics, Bukhara State Medical Institute, Bukhara, Uzbekistan

Keywords

orofacial pain; temporomandibular disorders; burning mouth syndrome; trigeminal neuralgia; quantitative sensory testing; conditioned pain modulation; bruxism; personalised pharmacotherapy

Full article

The PDF viewer is unavailable. Download the full article PDF.

How to cite

Giyazova M. M., Olimov S. Sh. (2026). From empirical to phenotype-guided pharmacotherapy of chronic orofacial pain: a structured review and quantitative synthesis of epidemiological, pharmacological, psychophysical and dental evidence. Journal of Taibah University Medical Sciences, 21(5), 1199–1207. DOI: 10.14419/j.jtumed.2026.10.12.